Literature DB >> 23384050

Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.

Ting Shi1, Christine S Moravec, Dianne M Perez.   

Abstract

Abstract Therapeutics to treat human heart failure (HF) and the identification of proteins associated with HF are still limited. We analyzed α(1)-adrenergic receptor (AR) subtypes in human HF and performed proteomic analysis on more uniform samples to identify novel proteins associated with human HF. Six failing hearts with end-stage dilated cardiomyopathy (DCM) and four non-failing heart controls were subjected to proteomic analysis. Out of 48 identified proteins, 26 proteins were redundant between samples. Ten of these 26 proteins were previously reported to be associated with HF. Of the newly identified proteins, we found several muscle proteins and mitochondrial/electron transport proteins, while novel were functionally similar to previous reports. However, we also found novel proteins involved in functional classes such as β-oxidation and G-protein coupled receptor signaling and desensitization not previously associated with HF. We also performed radioligand-binding studies on the heart samples and not only confirmed a large loss of β(1)-ARs in end-stage DCM, but also found a selective decrease in the α(1A)-AR subtype not previously reported. We have identified new proteins and functional categories associated with end-stage DCM. We also report that similar to the previously characterized loss of β(1)-AR in HF, there is also a concomitant loss of α(1A)-ARs, which are considered cardioprotective proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23384050      PMCID: PMC3624731          DOI: 10.3109/10799893.2013.764897

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  65 in total

Review 1.  Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure.

Authors:  A M Katz
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

2.  Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium.

Authors:  M Böhm; F Diet; G Feiler; B Kemkes; E Erdmann
Journal:  J Cardiovasc Pharmacol       Date:  1988-09       Impact factor: 3.105

3.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

4.  Inherited cardiomyopathies.

Authors:  D P Kelly; A W Strauss
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

5.  Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein.

Authors:  T Vago; M Bevilacqua; G Norbiato; G Baldi; E Chebat; P Bertora; G Baroldi; R Accinni
Journal:  Circ Res       Date:  1989-03       Impact factor: 17.367

6.  Alpha-1 adrenergic receptors in the nonfailing and failing human heart.

Authors:  M R Bristow; W Minobe; R Rasmussen; R E Hershberger; B B Hoffman
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

7.  Intracellular distribution of adrenoceptors in the failing human myocardium.

Authors:  C J Limas; C Limas; I F Goldenberg
Journal:  Am Heart J       Date:  1989-06       Impact factor: 4.749

8.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.

Authors:  M Ungerer; M Böhm; J S Elce; E Erdmann; M J Lohse
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

9.  Myocardial sulfhydryl pool alterations occur during reperfusion after brief and prolonged myocardial ischemia in vivo.

Authors:  E J Lesnefsky; I M Dauber; L D Horwitz
Journal:  Circ Res       Date:  1991-02       Impact factor: 17.367

10.  Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy.

Authors:  J Schaper; R Froede; S Hein; A Buck; H Hashizume; B Speiser; A Friedl; N Bleese
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more
  5 in total

1.  Pathway-based variant enrichment analysis on the example of dilated cardiomyopathy.

Authors:  Christina Backes; Benjamin Meder; Alan Lai; Monika Stoll; Frank Rühle; Hugo A Katus; Andreas Keller
Journal:  Hum Genet       Date:  2015-11-07       Impact factor: 4.132

2.  Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.

Authors:  Bradley S Lander; Yanling Zhao; Kohei Hasegawa; Mathew S Maurer; Albree Tower-Rader; Michael A Fifer; Muredach P Reilly; Yuichi J Shimada
Journal:  Front Cardiovasc Med       Date:  2022-06-17

Review 3.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

4.  Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.

Authors:  Yuichi J Shimada; Yoshihiko Raita; Lusha W Liang; Mathew S Maurer; Kohei Hasegawa; Michael A Fifer; Muredach P Reilly
Journal:  Circ Heart Fail       Date:  2021-07-01       Impact factor: 10.447

5.  Cardiac and Vascular α1-Adrenoceptors in Congestive Heart Failure: A Systematic Review.

Authors:  Gizem Kaykı-Mutlu; Olga Papazisi; Meindert Palmen; A H Jan Danser; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.